Massachusetts General Hospital and University of California Oakland have described 15-lipoxygenase (LOX) inhibitors reported to be useful for the treatment of stroke, among others.
The efficacy of allogeneic cell therapeutics for regenerative or oncology indications can be compromised by the emergence of antibodies against those cells, as observed in clinical trials. To overcome this limitation, scientists from the University of California and collaborators have developed a gene engineering approach providing antibody protection for cell therapeutics. The new approach to protecting cells from antibody-mediated cellular cytotoxicity (ADCC) relies on the overexpression of the IgG receptor CD64.
Poseidon Innovation LLC and the University of California have patented bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, viral infections and acute renal disorders, among others.
Researchers from the University of California and affiliated organizations have published data from a study that focused on screening of factors involved in hepatic low-density lipoprotein receptor (LDLR) regulation, with the aim of identifying potential new therapeutic targets in cardiovascular disease.
